Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mir-34
- Development stage
- Discontinued
- Lead developer
- Synlogic
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
mir-34 refers to the microRNA-34 family (miR-34a, miR-34b, and miR-34c), a group of small non-coding RNAs that function as master regulators of tumor suppression. These molecules are downregulated in numerous cancers and inhibit malignant growth by repressing genes involved in oncogenic signaling pathways. The primary mechanism is post-transcriptional silencing of target mRNAs that promote cancer cell viability, stemness, metastasis, and chemoresistance. The most studied member is miR-34a. Therapeutic strategies involve using synthetic mimics to restore or enhance the tumor-suppressive activity of endogenous mir-34[1][3].
- Other names
- microRNA-34microRNA34microRNA 34
02
Targets
ABCB1 (P-glycoprotein)CCND1 (Cyclin D1)NOTCH (Neurogenic locus notch homolog protein 3)Apoptosis regulator Bcl-2 mRNA
Beyond the preview
Go deeper on mir-34.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mir-34.